Brian J G Pereira
Overview
Explore the profile of Brian J G Pereira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mathur M, Sahay M, Pereira B, Rizk D
Indian J Nephrol
. 2024 Oct;
34(5):417-430.
PMID: 39372635
Immunoglobulin-A nephropathy (IgAN) is the most common primary glomerulonephritis in the world, with up to 40% of patients progressing to end-stage kidney disease (ESKD) within 30 years of diagnosis. IgAN...
2.
Mathur M, Barratt J, Chacko B, Chan T, Kooienga L, Oh K, et al.
N Engl J Med
. 2023 Nov;
390(1):20-31.
PMID: 37916620
Background: A proliferation-inducing ligand (APRIL) is implicated in the pathogenesis of IgA nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes APRIL. Methods: In this phase...
3.
Myette J, Kano T, Suzuki H, Sloan S, Szretter K, Ramakrishnan B, et al.
Kidney Int
. 2019 Apr;
96(1):104-116.
PMID: 31027890
IgA nephropathy (IgAN) is the most prevalent primary chronic glomerular disease for which no safe disease-specific therapies currently exist. IgAN is an autoimmune disease involving the production of autoantigenic, aberrantly...
4.
Fishbane S, Bolton W, Winkelmayer W, Strauss W, Li Z, Pereira B
Clin Nephrol
. 2012 Aug;
78(3):181-8.
PMID: 22874106
Background: Ferumoxytol is a unique intravenous (i.v.) iron therapy. This report examines factors affecting hemoglobin response to i.v. ferumoxytol, and the relationship between hematologic parameters, concomitant erythropoiesis-stimulating agents (ESA), and...
5.
Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira B
Clin J Am Soc Nephrol
. 2009 Jan;
4(2):386-93.
PMID: 19176796
Background And Objectives: Intravenous iron is a key component of anemia management for chronic kidney disease (CKD). Ferumoxytol is a unique intravenous iron product that can be administered as a...
6.
Gordon C, Balk E, Becker B, Crooks P, Jaber B, Johnson C, et al.
Am J Kidney Dis
. 2008 Oct;
52(5):811-25.
PMID: 18971009
KDIGO (Kidney Disease: Improving Global Outcomes) is an international initiative with a key mission of developing clinical practice guidelines in the area of chronic kidney disease (CKD). KDIGO recently published...
7.
Rao M, Li L, Demello C, Guo D, Jaber B, Pereira B, et al.
J Am Soc Nephrol
. 2008 Aug;
20(1):189-96.
PMID: 18684894
The role of mitochondrial injury in the pathogenesis of complications of uremia is incompletely defined, although diminished bioenergetic capacity and the accumulation of mitochondrial DNA (mtDNA) mutations have been reported....
8.
Spinowitz B, Kausz A, Baptista J, Noble S, Sothinathan R, Bernardo M, et al.
J Am Soc Nephrol
. 2008 Jun;
19(8):1599-605.
PMID: 18525001
Iron deficiency is an important cause of anemia in patients with chronic kidney disease (CKD), but intravenous iron is infrequently used among patients who are not on dialysis. Ferumoxytol is...
9.
Costa E, Pereira B, Rocha-Pereira P, Rocha S, Reis F, Castro E, et al.
Am J Nephrol
. 2008 Mar;
28(4):677-83.
PMID: 18354252
The aim of our study was to assess possible relations between prohepcidin, iron status and inflammatory markers in hemodialysis (HD) patients, as well as its association with resistance to recombinant...
10.
Rao M, Li L, Tighiouart H, Jaber B, Pereira B, Balakrishnan V
Nephrol Dial Transplant
. 2008 Mar;
23(8):2619-28.
PMID: 18334528
Background: Adiponectin (ADPN) levels are consistently elevated among patients with advanced chronic kidney disease, but its relationship with cardiovascular outcomes in this population remains controversial. Methods: We measured baseline and...